Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

CMPX

Compass Therapeutics (CMPX)

Compass Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CMPX
DateHeureSourceTitreSymboleSociété
17/06/202414h32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CMPXCompass Therapeutics Inc
30/05/202414h00GlobeNewswire Inc.Compass Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:CMPXCompass Therapeutics Inc
28/05/202422h10GlobeNewswire Inc.Compass Therapeutics Announces CEO TransitionNASDAQ:CMPXCompass Therapeutics Inc
23/05/202423h05GlobeNewswire Inc.Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual MeetNASDAQ:CMPXCompass Therapeutics Inc
14/05/202414h00GlobeNewswire Inc.Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:CMPXCompass Therapeutics Inc
13/05/202414h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CMPXCompass Therapeutics Inc
13/05/202414h00GlobeNewswire Inc.Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate UpdateNASDAQ:CMPXCompass Therapeutics Inc
25/04/202414h00GlobeNewswire Inc.Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously TreatedNASDAQ:CMPXCompass Therapeutics Inc
16/04/202414h00GlobeNewswire Inc.Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid TumorsNASDAQ:CMPXCompass Therapeutics Inc
12/04/202414h00GlobeNewswire Inc.Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual ConferenceNASDAQ:CMPXCompass Therapeutics Inc
10/04/202414h00GlobeNewswire Inc.Compass Therapeutics to Participate in the Stifel Targeted Oncology DaysNASDAQ:CMPXCompass Therapeutics Inc
09/04/202418h00GlobeNewswire Inc.Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:CMPXCompass Therapeutics Inc
21/03/202414h00GlobeNewswire Inc.Compass Therapeutics Reports 2023 Financial Results and Provides Corporate UpdateNASDAQ:CMPXCompass Therapeutics Inc
11/03/202415h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CMPXCompass Therapeutics Inc
29/02/202414h00GlobeNewswire Inc.Compass Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceNASDAQ:CMPXCompass Therapeutics Inc
28/02/202414h00GlobeNewswire Inc.Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical TrialNASDAQ:CMPXCompass Therapeutics Inc
05/01/202414h00GlobeNewswire Inc.Compass Therapeutics Provides Corporate UpdateNASDAQ:CMPXCompass Therapeutics Inc
09/11/202313h30GlobeNewswire Inc.Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:CMPXCompass Therapeutics Inc
07/11/202314h00GlobeNewswire Inc.Compass Therapeutics to Participate in Upcoming Investor EventsNASDAQ:CMPXCompass Therapeutics Inc
03/08/202314h00GlobeNewswire Inc.Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:CMPXCompass Therapeutics Inc
22/06/202322h05GlobeNewswire Inc.Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® IndexesNASDAQ:CMPXCompass Therapeutics Inc
04/05/202314h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CMPXCompass Therapeutics Inc
04/05/202314h30GlobeNewswire Inc.Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate UpdateNASDAQ:CMPXCompass Therapeutics Inc
27/04/202322h26Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:CMPXCompass Therapeutics Inc
26/04/202314h30GlobeNewswire Inc.Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQNASDAQ:CMPXCompass Therapeutics Inc
19/04/202314h30GlobeNewswire Inc.Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology DaysNASDAQ:CMPXCompass Therapeutics Inc
28/03/202314h30GlobeNewswire Inc.Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology SymposiumNASDAQ:CMPXCompass Therapeutics Inc
15/03/202313h30GlobeNewswire Inc.Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateNASDAQ:CMPXCompass Therapeutics Inc
14/02/202320h59Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CMPXCompass Therapeutics Inc
10/02/202322h02Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CMPXCompass Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CMPX